COX-2 INHIBITORS IN BLADDER CANCER
COX-2 inhibitors in bladder cancer: a rapid scoping review
BackgroundThis rapid scoping review assessed the feasibility of a COX-2 inhibition strategy for patients with transitional cell bladder cancer. The review was to support the Bladder COX-2 Inhibition Trial (BOXIT) proposal by the NCRI Bladder Cancer Clinical Study Group. The review mapped, but did not evaluate, the evidence base of the published literature on the effectiveness and cost-effectiveness of COX-2 inhibitors for transitional bladder cancer.
The literature search identified 129 records, four of which met the inclusion criteria. There were two published studies and two ongoing studies. The published studies comprised one non-randomised controlled trial and one case report (both published over 15 years ago), and the ongoing studies comprised two randomised controlled trials (RCTs). The results of this scoping exercise indicate that few studies exist for COX-2 inhibitors used for bladder cancer. There is no strong evidence base of existing published research in the area. Two RCTs of COX-2 inhibitors (alone or combined with other treatment) for bladder cancer, are ongoing.Conducted by: CRD and the NCRI Bladder Cancer Clinical Study Group
PublicationsCentre for Reviews and Dissemination. A rapid scoping review of the feasibility of a COX-2 inhibition strategy for patients with transitional cell bladder cancer. A report to the funders. 2004
Commissioned by the National Cancer Research Network